Weekly Recap: Foralumab Phase 2a completion and BTIG $7.00 target
Tiziana Life Sciences Ltd. (NASDAQ:TLSA) announced the final patient completed the Phase 2a INFORM—MS intranasal Foralumab trial in non—active SPMS with a database lock this week and 12—week topline data due October 2026, while BTIG left its $7.00 price target unchanged.Previous Week RecapThis is a…